

This is the first of a new Wednesday series on European MedTech. It was a week of steady, practical news rather than mega rounds: home dialysis and home stroke rehabilitation raised fresh money, sepsis and urology companies funded their next push across Europe, two European groups bought their way into new countries and new capabilities, two Korean companies cleared the MDR to enter Europe, and the European Parliament moved one step further on the MDR and IVDR revision.

1. Nextkidney raises more than €20M Series C for its portable home dialysis device

On 10 November Dutch medtech company Nextkidney said it had raised more than €20 million in a Series C round to complete development of the Neokidney, a portable hemodialysis device, and prepare it for market, with 3O Health among the investors and Dutch health insurers CZ, Menzis and Zilveren Kruis also involved. It is running a crowdfunding campaign through Invesdor for a further €3 million. The company reports 500 completed treatments across four medical centres in the Netherlands, Belgium and France, and this month starts a study in which patients perform 500 treatments independently outside the hospital. Subject to CE marking and FDA approval, it plans a first clinical launch at the end of 2027 and European home use in Q1 2028. It matters because European payers are putting their own money behind moving dialysis out of the hospital.

Source: Dealroom News

2. Bioliberty raises a €2.95M Series A extension to take stroke rehabilitation home

On 6 November Edinburgh and Boston based Bioliberty announced a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million). New backers are TGH Ventures (the investment arm of Tampa General Hospital), Ballad Ventures, Belfast based Whiterock and 25m Health. The company makes soft robotic upper limb rehabilitation technology, mainly for stroke survivors, and will use the money to extend it into the home, connect rehabilitation data across care settings and add AI decision support. It matters because rehabilitation after stroke is slowly moving from the clinic to the living room.

Source: EU-Startups

3. Efferon raises €4.3M to grow its sepsis blood purification devices

On 10 November Efferon, which develops hemoadsorption devices that remove endotoxins and excess inflammatory mediators from the blood, said it had raised €4.3 million from existing private investors in the DACH region. Its devices are approved and used across Europe, are distributed in 46 countries, and have been used in more than 30,000 treatments. The money supports expansion of Efferon LPS and Efferon NEO in Europe, India and Latin America, its network of 21 distributors, regulatory work and clinical evidence. The company reported revenue above €1.1 million in 2025 and expects intensive care revenue of about €5 million in 2027. It matters because a small European critical care company is funding growth from loyal investors while it prepares for a full Series A.

Source: Tech.eu

4. Active Medical Xcellence closes a seven figure round for urological endoscopy

On 9 November Jena based Active Medical Xcellence (AMX), a spinout of Active Fiber Systems, announced a seven figure growth round led by bm|t through the Thuringia Growth Equity Fund II, with MBG Thüringen, Sparkasse Jena Saale Holzland and a business angel joining. The money will expand sales and international reach for its MDR approved activeCut morcellator, used to treat benign prostatic obstruction, and develop its pipeline. It matters because regional public and savings bank capital in Germany is still backing small device makers that already carry an MDR certificate.

Source: bm|t

5. Two European deals: Rosti buys Alvi, and Eqwal buys the Preisler Group

On 9 November Malmö based Rosti Group announced it has acquired Alvi Group, adding five sites in Leksvik (Norway), Tyresö (Sweden), Wrocław (Poland) and Suzhou (China) and about 400 colleagues. Alvi adds EUR 50 million to Rosti's EUR 400 million in revenue, financial terms were not disclosed, and the acquisition took place on 2 November. On 6 November Eqwal Group announced the acquisition of the Preisler Group in Langen, Hesse, with 82 employees across technical orthopaedics, neurological therapy and assistive device distribution. It matters because European consolidation is happening quietly in the less glamorous parts of the chain, in contract manufacturing and in orthopaedic and rehabilitation care.

Source: PR Newswire (Rosti Group) and Eqwal Group

6. Two Korean companies win CE marking under the MDR

On 10 November Seoul based RF Medical announced CE marking under the EU MDR for its Mi-BLATOR microwave ablation system, covering both the generator and the antennas, following the MDR CE marking of its THYBLATE-V2 thyroid RFA electrode in September 2026. The same day Beamworks said its breast ultrasound AI software CadAI-B Dx received CE marking under the EU MDR as a Class IIb device, after its earlier FDA 510(k) clearance. It matters because companies from outside Europe are still investing the time and money to get through MDR, and Europe remains a market they want.

Source: PR Newswire (RF Medical) and Maeil Business (Beamworks)

7. MDR and IVDR revision: Parliament's IMCO committee adopts its opinion

On 10 November the European Parliament's Internal Market and Consumer Protection committee (IMCO) adopted its opinion on the MDR and IVDR revision, with all four negotiated compromise amendments winning a majority. The Budgets committee opinion is dated 5 November. The lead Public Health committee (SANT), with Oliver Schenk as rapporteur, has still not voted, the Legislative Observatory lists 14 December 2026 as an indicative plenary date, and health ministers meet on 8 December. Until a final text is adopted, which industry sources expect around Q2 to Q3 2027, the current MDR and IVDR apply in full and the transition deadlines of 31 December 2027, 2028 and 2029 are unchanged. It matters because every company planning a European launch is still working under today's rules.

Source: Pharma Deutschland and European Parliament Legislative Observatory

8. MedTech Europe calls for repeal of the SCIP database

On 4 November MedTech Europe and other associations published a joint statement asking EU policymakers to confirm the repeal of the SCIP database for substances of concern, as proposed by the European Commission under the Environmental Omnibus. They argue that after five years it duplicates information already required under REACH Article 33(1) and creates costly reporting, especially for SMEs and makers of complex products. It matters because the push to cut duplicated EU reporting now reaches well beyond the MDR itself.

Source: MedTech Europe

Gary's take

I want to put a gentle question mark over the MDR this week, because I am honestly not sure of the answer myself. My feeling is that the MDR has gone too far, and that a great deal of what it produces is Brussels bureaucracy rather than safer patients. Many good new products simply never reach the European market, and companies quietly launch in the US or Asia first, or not in Europe at all. Is that good or bad? Some will say it protects patients, and I respect that view. But when I look at hospitals around Europe, I believe European healthcare is paying a price, and most people are not aware of it. The technology world knows, but I am not sure doctors, healthcare reformers, or even the people who run the MDR see what is missing from their own clinics. This week's news shows both sides, with companies like AMX, RF Medical and Beamworks getting through, and Brussels still debating how to simplify. I would love to hear what you see from where you sit.

Has the MDR made European patients safer, or has it mainly kept good technology away from them? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

If you'd like to follow along, you can find us here:

Website: synergenmedtech.com
LinkedIn: linkedin.com/company/100981535
YouTube: youtube.com/@synergenmedtech

Sources note: all items were found through a public web scan of about 4 to 11 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. No new EIC Accelerator or Horizon results for medtech were published in this window, and no new MDR notified body designation was found.